AGEN 1571
Alternative Names: AGEN-1571Latest Information Update: 27 Jan 2026
At a glance
- Originator Agenus
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Leukocyte immunoglobulin-like receptor B1 antagonists; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Jan 2026 Phase I development for Solid-tumours (Combination therapy, Late-stage disease, Metastatic disease, Monotherapy) is ongoing in the US (IV)
- 23 Dec 2024 Agenus completes a Phase-I trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in USA (NCT05377528)
- 19 Jul 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT05377528)